8/1/26 Author Claude Fable & Jeremy Smith

A Case For Cautious Medical Tourism in Mexico

We at Longevity Smith are founded on the conviction that longevity and healthspan are for everyone, not just people with platinum insurance and six-figure savings. A hip that works, teeth that chew, a metabolism brought under control before it becomes diabetes — these are not luxuries. They are the raw material of a long, functional life. So when more than a million Americans a year cross the southern border for medical care, the right response is not reflexive alarm. It is to ask, honestly: why are they going, what are the real risks, and how can they go safely?

I will be upfront about where I land. After weighing the evidence, I am cautiously pro medical tourism, done carefully, for the right procedures, at the right facilities. But 'cautiously' and 'carefully' are doing real work in that sentence, because the risks are documented and some of them are severe. This post lays out the full picture: the American problem that drives the phenomenon, the honest risk ledger, the data gap nobody talks about, the underappreciated evidence on the other side, and a concrete framework for deciding.

The American Problem: Priced Out and Underperforming

Any fair debate about medical tourism has to start with the baseline it is being compared to, and the baseline is worse than most Americans assume, on both affordability and results.

Start with results. The Commonwealth Fund's Mirror, Mirror 2024 report, its eighth international comparison, analyzed 70 performance measures across 10 high-income countries. The United States ranked last overall, and last specifically on access to care, equity, and health outcomes, despite spending more on healthcare than any other nation in the study, over 16 percent of gross domestic product. Americans in the comparison live the shortest lives and suffer the most avoidable deaths. The two top performers, Australia and the Netherlands, achieve their results while spending the smallest share of their economies on healthcare. The common assumption that American medicine is categorically the world's best holds true at the elite tertiary tier, in complex oncology, transplantation, and research medicine, but it is flatly false as a description of what the average American actually receives for what they pay.

Now affordability. Roughly 100 million Americans, about 41 percent of adults, carry debt from medical or dental bills, according to Kaiser Family Foundation research. An estimated half a million United States bankruptcies each year involve medical bills or illness-related income loss. Gallup polling has found record shares of Americans, nearly four in ten, reporting that they or a family member delayed medical treatment because of cost. Roughly 26 million remain uninsured entirely, and tens of millions more are underinsured, technically covered but facing deductibles that make actually using the coverage ruinous.

Here is why this matters for the debate: foregone care is not a neutral outcome. It is itself a health risk, and often the largest one on the table. An untreated bone-on-bone hip means years of immobility, deconditioning, and decline. Untreated obesity means progression toward diabetes, cardiovascular disease, and shortened healthspan. Untreated dental disease is linked to cardiovascular and systemic inflammation. When critics of medical tourism say 'stay home,' they are frequently prescribing, in practice, 'go without,' and going without has a body count that never shows up in medical tourism statistics because nobody attributes those deaths to a trip that was never taken.

The Honest Risk Ledger

Being pro-tourism does not mean pretending the risks away. They are real, documented, and worth stating at full strength, because respecting them is precisely what separates the patients who do well from the patients who make the news.

Continuity of care is the structural weakness, and the professional societies say so

Surgery is a process, not an event. The most dangerous bariatric complications, anastomotic leaks, strictures, and deep infections, often present two to six weeks after the operation, long after the patient has flown home. The American Society for Metabolic and Bariatric Surgery (ASMBS) formally holds that extensive travel for bariatric surgery should be discouraged unless appropriate follow-up and continuity of care are arranged and medical records transfer adequately. Notably, the ASMBS deliberately avoided framing this as a foreign-country problem. It coined the term 'global bariatric healthcare,' defined as travel across any distance that precludes routine follow-up with the operating surgeon or program, meaning a Texan flying to a New York surgeon has the same structural problem as one flying to Tijuana. That reframing matters: the risk is distance without follow-up, not Mexico per se, and it is a risk that planning can substantially mitigate.

When continuity fails, it fails expensively. Studies of returning medical tourists find that roughly two-thirds of those who develop complications seek emergency care in the United States, most American insurance plans exclude complications of elective foreign surgery, and a 2025 academic center study at the border found the mean hospital charge for treating an anastomotic leak exceeded $400,000. Add the independent risk that flying soon after major surgery elevates deep vein thrombosis and pulmonary embolism risk, and the case for building recovery time into the plan, rather than racing home, is overwhelming.

The infection record is documented, and one study should be required reading

The Centers for Disease Control and Prevention (CDC) has investigated multiple outbreaks tied to medical tourism in Mexico, and the single most rigorous piece of evidence in this entire debate is the peer-reviewed investigation published in Emerging Infectious Diseases in 2022. It traced an outbreak of extensively drug-resistant, carbapenemase-producing Pseudomonas aeruginosa, a pathogen resistant to nearly all antibiotics and rare in the United States, among American bariatric tourists to Tijuana during 2018 and 2019. Investigators identified 38 case-patients across 18 states. The comparison statistic is devastating: serious complications from laparoscopic sleeve gastrectomy in the United States run roughly 1 to 2 percent, while more than 40 percent of the outbreak's case-patients required postoperative hospitalization back home.

Then there is Matamoros. In 2023, contaminated epidural anesthesia at two unaccredited cosmetic surgery clinics there caused the largest outbreak of Fusarium solani fungal meningitis on record among United States patients, infecting roughly two dozen people and killing at least seven women, with follow-up clinical reporting placing the toll higher. That same year, four Americans on a trip connected to a cosmetic procedure in Matamoros were kidnapped after being caught in cartel crossfire; two were killed. Tamaulipas, where Matamoros sits, carries the State Department's highest 'Do Not Travel' advisory, and had for years before these events.

Legal recourse is thin

An American injured by malpractice at home has jurisdiction, discovery, regulatory boards, and accessible litigation. United States courts have little to no authority over foreign providers, and Mexico's national medical arbitration body, the Comisión Nacional de Arbitraje Médico (CONAMED), resolves only a minority of cases with any financial payment to the patient. Choosing surgery abroad means largely waiving the legal protections that discipline American medicine. This is a real cost, and it should be priced into the decision, not discovered afterward.

The Data Problem Both Sides Ignore

Now the debate's biggest structural weakness, one that almost no article on this subject admits: nobody knows the actual complication rate of medical tourism, because every statistic in circulation is a numerator without a denominator. Outbreak investigations, emergency department case series, and border hospital studies count patients who returned with problems. Nobody counts the total number of procedures performed, so no true rate can be computed. There is no outcome registry for medical tourism. The ASMBS's own position statement concedes that outcome statistics from internationally accredited hospitals abroad are rare, while anecdotal reports, both glowing testimonials and horror stories, are numerous.

This cuts both ways, and intellectual honesty demands saying so. Skeptics cannot prove that vetted Mexican care is statistically worse than American care, and advocates cannot prove that the accredited tier performs at American benchmark levels. Marketing claims of '95 percent success rates' from clinic websites deserve exactly as much skepticism as viral horror stories. What the evidence does support is a narrower, more useful claim: the documented catastrophes cluster overwhelmingly in a specific segment, unaccredited, price-driven clinics, often in high-advisory regions, frequently reached through social media marketing. The Emerging Infectious Diseases outbreak traced 31 of its 38 cases to a single surgeon, and the implicated facility, found to have infection-control lapses, closed in 2019. The Matamoros clinics were unaccredited storefronts in a maximum-advisory state. The failures are real, and they are also concentrated, which is exactly what you would expect if provider selection, not national borders, is the variable that matters.

The Case for Going, Carefully

A genuine top tier exists, and it is verifiable

Mexico has roughly nine hospitals accredited by Joint Commission International (JCI), the international arm of the same body that accredits United States hospitals, applying comparable standards. Médica Sur in Mexico City, consistently ranked Mexico's top hospital, maintains a formal affiliation with the Mayo Clinic. Mexico City, Monterrey, and Guadalajara host teaching hospitals and research centers delivering advanced cardiac, oncologic, and orthopedic care, staffed heavily by physicians who trained in the United States or Europe. The price gap at this tier reflects physician compensation norms and administrative overhead, a specialist earning $150,000 in Mexico City may hold the same credentials as a counterpart earning $600,000 in Houston, not inferior training.

American insurers already underwrite Mexican care

This is the most underappreciated evidence in the whole debate, because it is not an anecdote; it is an actuarial judgment. Blue Shield of California operates Access Baja, a cross-border Health Maintenance Organization built for employees and dependents to receive their routine care in Mexico. SIMNSA (Sistemas Medicos Nacionales), the first Mexican Health Maintenance Organization licensed as a healthcare service plan by the State of California, runs a network of over 700 physicians across Tijuana, Tecate, and Mexicali, and its plans are Affordable Care Act-compliant. Regulated American insurance companies, with actuaries, medical directors, and liability exposure, have concluded that networked Mexican providers meet an insurable standard of care, and California's regulators licensed the arrangement. That is an institutional endorsement no marketing brochure can match.

Volume matters, and the top Mexican programs have it

Surgical outcomes correlate strongly with surgeon and facility case volume; this is one of the most consistent findings in the outcomes literature. The leading Mexican bariatric and dental programs are volume machines, performing thousands of cases annually, more than most American community surgeons see in a career stage. A surgeon who performs 800 sleeve gastrectomies a year at a purpose-built facility is not obviously a downgrade from a domestic surgeon who performs 60, whatever the two countries' averages look like.

The economics are not marginal, and risk is regional

A gastric sleeve priced at $15,000 to $25,000 out of pocket domestically runs $4,000 to $7,000 in Mexico. Dental implants quoted at $3,000 to $6,000 cost a fraction of that. Hip and knee replacements listed at $35,000 to $50,000 are available around $9,500 to $15,000. Documented savings across procedures range from roughly 36 to 89 percent, and CDC surveillance confirms medical tourism skews toward the uninsured, with Mexico the top destination. Meanwhile, the State Department's advisory map is not uniform: Yucatán and Campeche sit at the lowest level, and many patient destinations carry the same 'exercise increased caution' rating applied to major European cities. Using Tamaulipas cartel violence to indict a Monterrey teaching hospital is like using one city's crime statistics to warn people away from a hospital in another state.

A Note on Pharmacy Tourism

One category deserves its own warning label, because it is actually the largest slice of cross-border medical travel: prescription drug purchasing. Its risk profile is entirely different from surgical tourism, and in one respect worse. The CDC and State Department have warned about counterfeit pills sold at some Mexican pharmacies, pills laced with fentanyl and methamphetamine, and researchers have documented the problem in tourist-area storefronts. Legitimate pharmaceuticals at legitimate Mexican pharmacies are a real savings channel, but loose pills from tourist-strip counters are a gamble with a synthetic-opioid downside. If medication savings are the goal, the vetting burden is no lighter than for surgery; it is just different.

The Framework: How to Be the Right Kind of Patient

The evidence supports neither prohibition nor cheerleading. It supports a decision tree, and the decision tree is not complicated.

• Favorable candidates: routine dentistry, LASIK and ophthalmology, imaging and diagnostics, and high-volume, accredited bariatric or orthopedic programs in major urban centers, chosen by patients willing to do the vetting work.

• Unfavorable candidates: complex oncology, cardiac surgery, transplant care, patients with unstable medical conditions, anyone choosing primarily on price or social media marketing, and anyone unwilling to plan for complications before they happen.

• Non-negotiables if you go: accredited facility only, verified directly through the accreditor, not the clinic's website; independently confirmed surgeon board certification through Mexican specialty councils; a written complication plan, including a United States physician who has agreed in advance to manage follow-up; complete copies of all records, implant and device documentation before you fly; no travel through Level 3 or Level 4 advisory states for any reason, including cheaper flights; and enough in-country recovery time that you are cleared by your surgeon, not merely discharged, before boarding a plane.

The Bottom Line

The catastrophes are real: a drug-resistant outbreak traced to one Tijuana surgeon, a fatal meningitis cluster in unaccredited Matamoros clinics, kidnappings in a maximum-advisory state, six-figure complication bills that nobody covers. Every one of them argues for vetting, planning, and respect for the risks. What none of them establishes is that the internationally accredited, insurer-networked, high-volume tier of Mexican medicine is unsafe, and the quiet verdict of American insurance regulators and actuaries suggests the opposite.

Meanwhile, the system these patients are leaving ranks last among its high-income peers on access, equity, and outcomes while charging the most, has loaded 100 million of its citizens with medical debt, and leaves nearly four in ten families delaying care over cost. Against that baseline, a carefully chosen Mexican hospital is not the reckless option. For millions of people, it is the only realistic path to the working joints, sound teeth, and controlled metabolic health that a long healthspan is built on. Healthspan should not be a luxury good. Until American healthcare acts like it believes that, informed medical tourism is not a fringe gamble. It is a rational, defensible response, provided you go as the patient who did the homework, and not the one who found a deal on Instagram.